Literature DB >> 16842220

The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR).

E Teodori1, S Dei, C Martelli, S Scapecchi, F Gualtieri.   

Abstract

Multidrug resistance (MDR) is a kind of acquired resistance of microorganisms and cancer cells to chemotherapic drugs that are characterized by different chemical structure and different mechanism of action. Classic MDR is the consequence of the over-expression of a variety of proteins that extrude the chemotherapic from the cell, lowering its concentration below the effective one. The ABC (ATP Binding Cassette) is a ubiquitous and important family of such transporter proteins. Members of this super family are present in mammals as well as in prokaryotic organisms and use ATP as the energy source to activate the extrusion process. P-glycoprotein (Pgp) and Multidrug Resistance Proteins (MRP1 and sister proteins) are the most important and widely studied members of ABC super family. Our knowledge about the structures and functions of transporter proteins has definitely improved in recent years, following the resolution of the structure of bacterial pumps which opened the way to the building of homology models for the more complex Pgp and MRP. It can be anticipated that these results will have a strong impact on the design of more potent and safer MDR reverters. A huge number of small molecules, many of natural origin, are able to reverse multidrug resistance by inhibiting the functions of Pgp, MRP1 and sister proteins and their action has been considered a possible way to reverse MDR. However, while a few compounds have reached clinical trials, none of them has, so far, been cleared for therapeutic use. Two main reasons are at the base of this difficulty: i) MDR is a complex phenomenon that may arise from several different biochemical mechanisms, with the consequence that inhibition of transporter proteins may be insufficient to reverse it; ii) the physiological role of Pgp and sister proteins requires more potent modulators with proper selectivity and pharmacokinetic in order to avoid unwanted side effects. This paper first reviews the most recent discoveries on the structures and functions of the ABC super family, in particular Pgp and MRP. Then, the medicinal chemistry of MDR reverters, in light of these findings, is discussed and the molecules that are presently in development are reviewed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16842220     DOI: 10.2174/138945006777709520

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  52 in total

Review 1.  Nanomedicinal strategies to treat multidrug-resistant tumors: current progress.

Authors:  Xiaowei Dong; Russell J Mumper
Journal:  Nanomedicine (Lond)       Date:  2010-06       Impact factor: 5.307

2.  Computational predictive models for P-glycoprotein inhibition of in-house chalcone derivatives and drug-bank compounds.

Authors:  Trieu-Du Ngo; Thanh-Dao Tran; Minh-Tri Le; Khac-Minh Thai
Journal:  Mol Divers       Date:  2016-07-18       Impact factor: 2.943

3.  CIP2A is associated with multidrug resistance in cervical adenocarcinoma by a P-glycoprotein pathway.

Authors:  Juan Liu; Meng Wang; Xiaoli Zhang; Qingwei Wang; Mei Qi; Jing Hu; Zhiqiang Zhou; Chunyan Zhang; Weifang Zhang; Weiming Zhao; Xiao Wang
Journal:  Tumour Biol       Date:  2015-09-24

4.  Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

Authors:  James A McCubrey; Linda S Steelman; Richard A Franklin; Steven L Abrams; William H Chappell; Ellis W T Wong; Brian D Lehmann; David M Terrian; Jorg Basecke; Franca Stivala; Massimo Libra; Camilla Evangelisti; Alberto M Martelli
Journal:  Adv Enzyme Regul       Date:  2007-03-26

5.  ATP-binding cassette transporters modulate both coelenterazine- and D-luciferin-based bioluminescence imaging.

Authors:  Ruimin Huang; Jelena Vider; Inna Serganova; Ronald G Blasberg
Journal:  Mol Imaging       Date:  2011-06       Impact factor: 4.488

6.  Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3β/β-catenin signalling.

Authors:  Kun Zhang; Haixing Song; Ping Yang; Xiaozhen Dai; Ya Li; Lan Wang; Jun Du; Kejian Pan; Tao Zhang
Journal:  Cell Prolif       Date:  2015-01-21       Impact factor: 6.831

Review 7.  Drug Transporters and Na+/H+ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 Proteins.

Authors:  Dustin R Walsh; Thomas D Nolin; Peter A Friedman
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

8.  The synthesis and characterization of cellular membrane affinity chromatography columns for the study of human multidrug resistant proteins MRP1, MRP2 and human breast cancer resistant protein BCRP using membranes obtained from Spodoptera frugiperda (Sf9) insect cells.

Authors:  Prateek A Bhatia; Ruin Moaddel; Irving W Wainer
Journal:  Talanta       Date:  2010-02-25       Impact factor: 6.057

9.  Modulation of P-glycoprotein expression by triptolide in adriamycin-resistant K562/A02 cells.

Authors:  Hao Li; Lulu Hui; Wenlin Xu; Huiling Shen; Qiaoyun Chen; Lulu Long; Xiaolan Zhu
Journal:  Oncol Lett       Date:  2011-11-30       Impact factor: 2.967

10.  Multifunctional nanoparticles based on a single-molecule modification for the treatment of drug-resistant cancer.

Authors:  Dun Wang; Jingling Tang; Yongjun Wang; Srinivas Ramishetti; Qiang Fu; Kelly Racette; Feng Liu
Journal:  Mol Pharm       Date:  2013-03-19       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.